Bladder cancer: A Guide by Dr. Ramani

🌟 We are honored to introduce Mila Ogalla Toledo (Spain) as a speaker at the Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer Conference, happening online from December 6-8, 2024! Mila Ogalla Toledo will present on “Early Onset Cancer Diagnosis: Age Should Never Be a Barrier to Receiving the Appropriate Care and Attention.” This session will challenge age-related biases and emphasize the need for equitable, patient-centered care in addressing early-onset cancers. 📅 Save the date and join us for three days of transformative discussions and insights with global experts, patients, and advocates in the field of colorectal cancer. 👉 To learn more or register, follow the link below: https://lnkd.in/dNgP7N6U #GlobalCancerMovement #ColorectalCancer #EarlyOnsetCancer #OncoDaily #CancerCare #Oncology

Dana-Farber Cancer InstituteAlicia SimonsShelby Janner #PalliativeCare #SupportiveCare #Oncology #CancerCare #BreastCancerAwareness #QualityOfLife #PatientCare #CompassionateCare #HealthcareInnovationLaura Carfang Surviving Breast Cancer I recently joined the Breast Cancer Conversations podcast to talk about the role of palliative and supportive care in cancer treatment. Palliative care isn’t just about end-of-life support. It’s a way to improve the quality of life for patients and their families, starting early in treatment. This approach can make a real difference in outcomes and experiences. During the episode, I shared some of what I’ve learned over my years at Dana-Farber Cancer Institute and through my work with oncology teams.. You can listen to the episode here: https://lnkd.in/d9UGnBaH

🩷 Pink October: Making the invisible visible This Breast Cancer Awareness Month, we focus on the unseen insights that can transform treatment outcomes. With the OncoDEEP® Kit, we’re helping oncologists make the invisible visible—uncovering critical genetic mutations that traditional tests may miss. 🧬 Discover in our Case of the Month how our analysis has revealed key mutations like PIK3CA and ESR1, which guide more personalized, effective treatments for metastatic breast cancer patients. These insights empower oncologists to adjust therapies, improving outcomes and offering renewed hope. 💪 Swipe through our carousel to see how we’re revolutionizing cancer care by making the invisible, visible. 🎗️ Discover the full case : https://lnkd.in/e8aCmiM8 Resources about breast cancer : https://lnkd.in/e95wwe7g #PinkOctober #MakingTheInvisibleVisible #BreastCancerAwareness #OncoDEEP #PrecisionMedicine #GenomicProfiling #OncoDNA

#pancreaticcancer : A call to action launched by the Pancreatic Cancer Action Network after the publications of the American Cancer Society "cancer facts and figures 2025". >>> No other major cancer has a five-year survival rate less than 20%! <<< The PanCAN is focusing its efforts on: > Pioneering the advancement of an early detection strategy for pancreatic cancer. > Revolutionizing the development of advanced and personalized treatments. > Empowering #patients and #caregivers with the resources and knowledge they need to advocate for the #care they deserve. ACOBIOM is participating to these actions in providing its predictive diagnostics to better target 1st-line therapies and to personalize treatments. Thank you to the PanCAN team for all its work, actions, and efforts, for being the catalyst for changes in pancreatic cancer! Julie Fleshman Tammy Buist Anna Berkenblit Lynn Matrisian Didier Ritter David Piquemal #personalizedmedicine #precisionmedicine #targetedtherapy https://lnkd.in/dNDmaJ9P

- #ESMOCONFERENCE Highlights 🚀 Game-Changer in Breast Cancer Treatment! 🚀 #Radiationtherapy for women with #breastcancer will now last for no more than three weeks At the recent #ESMOconference, groundbreaking results from the Phase III HypoG-01 study were unveiled. Led by #DrSofiaRivera at Gustave Roussy and sponsored by Unicancer, this landmark study has significant implications for breast cancer management worldwide. 🔬 Key Findings: Study Design: Phase III HypoG-01, the first global study to prospectively and randomly compare radiation therapies. Results: #Hypofractionated radiation therapy (15 sessions over 3 weeks) is equivalent to #normofractionated therapy (25 sessions over 5 weeks) for locoregional breast cancer. Impact: This three-week course now become the new standard of care for women with node-invasive breast cancer. This pivotal study sets a new #benchmark in treatment efficiency and patient care. https://lnkd.in/dq3mm_aP #BreastCancer #RadiationTherapy #ESMO2024 #CancerResearch #HealthcareInnovation #DataMIntelligence

DataM Intelligence, we specialize in providing strategic #insights and #competitiveintelligence to help companies stay ahead of such #innovations in the #healthcare landscape. From clinical trial monitoring to market #opportunity analysis, we support pharma and biotech companies in identifying game-changing developments like this and understanding their potential impact. Let’s connect if you’re interested in how we can assist your organization in navigating these breakthroughs and leveraging them for growth.

Did you know that breast cancer is the most common cancer worldwide, with 2.3 million new cases each year? October is Breast Cancer Awareness Month - a crucial time to highlight that early detection, screening and treatment of breast cancer can save lives. At LifeSci Consulting and LifeSci Partners, we are dedicated to supporting the World Health Organization's Global Breast Cancer Initiative to save 2.5 million lives by 2040. We are proud to work alongside companies that are advancing breast cancer screening, diagnostics, and treatments for patients globally. #BreastCancerAwarenessMonth #BCAM2024 #WomensHealth #Diagnostics #PersonalizedTreatments

Survival Chances of Lung Cancer with Early Diagnosis In this video, Dr Jovita Martin Daniel, a renowned oncologist at MGM Cancer Institute, shares insights into the survival rates of lung cancer when detected early. Discover how early diagnosis, combined with advanced treatments, can greatly improve a patient’s chances of survival and quality of life. Timely detection can save lives. Learn more about the importance of regular screenings, early symptoms, and the latest breakthroughs in lung cancer care. 🔗 Learn more about Dr. Jovita Martin Daniel: [https://lnkd.in/gwdNNJS8) #LungCancer #EarlyDiagnosis #CancerSurvival #DrJovitaMartinDaniel #CancerTreatment #OncologyCare #MGMCares #WeCureFearFirst #CancerAwareness #LungCancerSurvival #CancerScreening #PatientCare #Oncology #MGMCancerInstitute #FightingCancer

July 2024 Issue of Strategies Oncology magazine - Solid information for Smart Decisions-  The theme this month is From "Cancer Victim" to "Cancer Survivor” As usual, Strategies offers different perspectives on important issues. In This Issue: Clinic Helps Breast Cancer Survivors Navigate Their “Next Steps”  by Jessica J. Reed, PhD The American Cancer Society estimates that there are more than 4 million breast cancer survivors in the United States, more than any other type of cancer. That number continues to grow annually thanks to early detection and advances in treatment options. In fact, when caught in its earliest, localized stages, breast cancer has a 99% five-year relative survival rate. https://lnkd.in/g6h7pz5G #STRATEGIESONCOLOGYMAGAZINE #Oncology #cancercare #breastcancersurvivors #nextstepsbreastcancer #onealcancercenter American Cancer Society

Listen to Dr. Isaac Garcia-Murillas from The Institute of Cancer Research and Dr. Richard Chen, CMO and EVP of R&D, Personalis, discuss a study with leading world experts in breast cancer (Dr. Nicholas Turner from The Royal Marsden NHS Foundation Trust) highlighting how NeXT Personal® was able to detect the smallest traces of cancer in the blood (ctDNA) a median of ~15 months ahead of scans in a cohort of 78 patients with breast cancer (all subtypes).   In this robust study, median follow-up time was ~6 years and researchers analyzed 619 plasma samples (a median of 8 samples per patient).   Learn about the results of ultra-sensitive MRD testing with NeXT Personal in Breast Cancer. #PrecisionOncology #LiquidBiopsy #MRD #ctDNA #BreastCancer #BreastCancerAwarenessMonth